ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity

Pharmaceutical Technology

KOLs note that CagriSema could cannibalise semaglutide's market share in obesity due to its improved weight loss and HbA1c reduction efficacy.

pharminent April 2, 2026 (Last updated: April 2, 2026)

Pharmaceutical Technology

KOLs note that CagriSema could cannibalise semaglutide’s market share in obesity due to its improved weight loss and HbA1c reduction efficacy.

Related Stories